JP2005504039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504039A5 JP2005504039A5 JP2003518518A JP2003518518A JP2005504039A5 JP 2005504039 A5 JP2005504039 A5 JP 2005504039A5 JP 2003518518 A JP2003518518 A JP 2003518518A JP 2003518518 A JP2003518518 A JP 2003518518A JP 2005504039 A5 JP2005504039 A5 JP 2005504039A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrol
- guanidine
- compound according
- propylideneamino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 239000003814 drug Substances 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 6
- 125000004432 carbon atoms Chemical group C* 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- -1 methylenedioxy Chemical group 0.000 claims 4
- 206010061428 Decreased appetite Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 206010061255 Ischaemia Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 210000003491 Skin Anatomy 0.000 claims 2
- 208000006641 Skin Disease Diseases 0.000 claims 2
- 206010040829 Skin discolouration Diseases 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- JPCUXDJNKAPCAK-UHFFFAOYSA-N 1-[3-[1-[3-(butylamino)-4-methylphenyl]-4-methylpyrrol-2-yl]propylidene]guanidine Chemical compound C1=C(C)C(NCCCC)=CC(N2C(=CC(C)=C2)CCC=NC(N)=N)=C1 JPCUXDJNKAPCAK-UHFFFAOYSA-N 0.000 claims 1
- SZBYBKFFPPRNGM-UHFFFAOYSA-N 2-[(1-phenylpyrrol-2-yl)methylideneamino]guanidine Chemical compound NC(=N)NN=CC1=CC=CN1C1=CC=CC=C1 SZBYBKFFPPRNGM-UHFFFAOYSA-N 0.000 claims 1
- MXSSGIKKSQQVML-UHFFFAOYSA-N 2-[(1-phenylpyrrol-3-yl)methylideneamino]guanidine Chemical compound C1=C(C=NNC(=N)N)C=CN1C1=CC=CC=C1 MXSSGIKKSQQVML-UHFFFAOYSA-N 0.000 claims 1
- FTLVJMKQHHAPPQ-UHFFFAOYSA-N 2-[(4-butoxy-1-phenylpyrrol-3-yl)methylideneamino]guanidine Chemical compound C1=C(C=NNC(N)=N)C(OCCCC)=CN1C1=CC=CC=C1 FTLVJMKQHHAPPQ-UHFFFAOYSA-N 0.000 claims 1
- BVPJBFYWDFGEQD-UHFFFAOYSA-N 2-[(5-tert-butyl-1-phenylpyrrol-2-yl)methylideneamino]guanidine Chemical compound CC(C)(C)C1=CC=C(C=NNC(N)=N)N1C1=CC=CC=C1 BVPJBFYWDFGEQD-UHFFFAOYSA-N 0.000 claims 1
- PNFQDVYJQBKEKG-UHFFFAOYSA-N 2-[2-[1-(4-pyrrol-1-ylphenyl)pyrrol-2-yl]ethylideneamino]guanidine Chemical compound NC(=N)NN=CCC1=CC=CN1C1=CC=C(N2C=CC=C2)C=C1 PNFQDVYJQBKEKG-UHFFFAOYSA-N 0.000 claims 1
- INAGMDJKDCMGBN-UHFFFAOYSA-N 2-[2-[4-tert-butyl-1-[4-methoxy-2-(propylamino)phenyl]pyrrol-3-yl]ethylideneamino]guanidine Chemical compound CCCNC1=CC(OC)=CC=C1N1C=C(C(C)(C)C)C(CC=NNC(N)=N)=C1 INAGMDJKDCMGBN-UHFFFAOYSA-N 0.000 claims 1
- VEAZGZRETIXYKD-UHFFFAOYSA-N 2-[3-(1-phenylpyrrol-2-yl)propylideneamino]guanidine Chemical compound NC(=N)NN=CCCC1=CC=CN1C1=CC=CC=C1 VEAZGZRETIXYKD-UHFFFAOYSA-N 0.000 claims 1
- ZPSSSNXLXNAUJN-UHFFFAOYSA-N 2-[3-(4-methoxy-1-phenylpyrrol-2-yl)propylideneamino]guanidine Chemical compound C1=C(OC)C=C(CCC=NNC(N)=N)N1C1=CC=CC=C1 ZPSSSNXLXNAUJN-UHFFFAOYSA-N 0.000 claims 1
- OATSWRMBGTVFEB-UHFFFAOYSA-N 2-[3-(4-methyl-1-phenylpyrrol-3-yl)propylideneamino]guanidine Chemical compound C1=C(CCC=NNC(N)=N)C(C)=CN1C1=CC=CC=C1 OATSWRMBGTVFEB-UHFFFAOYSA-N 0.000 claims 1
- WSUCPDFYFNIGET-UHFFFAOYSA-N 2-[3-(5-methoxy-1-phenylpyrrol-3-yl)propylideneamino]guanidine Chemical compound COC1=CC(CCC=NNC(N)=N)=CN1C1=CC=CC=C1 WSUCPDFYFNIGET-UHFFFAOYSA-N 0.000 claims 1
- VRLSOCNICDJRMA-UHFFFAOYSA-N 2-[3-[1-(2-bromo-3-chlorophenyl)pyrrol-3-yl]propylideneamino]guanidine Chemical compound C1=C(CCC=NNC(=N)N)C=CN1C1=CC=CC(Cl)=C1Br VRLSOCNICDJRMA-UHFFFAOYSA-N 0.000 claims 1
- MHSDJUAWOGTJAH-UHFFFAOYSA-N 2-[3-[1-(2-hydroxyphenyl)pyrrol-2-yl]propylideneamino]guanidine Chemical compound NC(=N)NN=CCCC1=CC=CN1C1=CC=CC=C1O MHSDJUAWOGTJAH-UHFFFAOYSA-N 0.000 claims 1
- JOSCROVGIFIWEN-UHFFFAOYSA-N 2-[3-[1-(2-nitro-4-phenylphenyl)pyrrol-2-yl]propylideneamino]guanidine Chemical compound NC(=N)NN=CCCC1=CC=CN1C1=CC=C(C=2C=CC=CC=2)C=C1[N+]([O-])=O JOSCROVGIFIWEN-UHFFFAOYSA-N 0.000 claims 1
- VQQGUAUMDBAFJR-UHFFFAOYSA-N 2-[3-[1-(2-nitrophenyl)pyrrol-2-yl]propylideneamino]guanidine Chemical compound NC(=N)NN=CCCC1=CC=CN1C1=CC=CC=C1[N+]([O-])=O VQQGUAUMDBAFJR-UHFFFAOYSA-N 0.000 claims 1
- JHIYVRCHJLREML-UHFFFAOYSA-N 2-[3-[1-(2-tert-butylphenyl)-4-chloro-5-methylpyrrol-2-yl]propylideneamino]guanidine Chemical compound CC1=C(Cl)C=C(CCC=NNC(N)=N)N1C1=CC=CC=C1C(C)(C)C JHIYVRCHJLREML-UHFFFAOYSA-N 0.000 claims 1
- NTPYMXGRGQYCJI-UHFFFAOYSA-N 2-[3-[1-(3-fluorophenyl)-5-methylpyrrol-3-yl]propylideneamino]guanidine Chemical compound CC1=CC(CCC=NNC(N)=N)=CN1C1=CC=CC(F)=C1 NTPYMXGRGQYCJI-UHFFFAOYSA-N 0.000 claims 1
- DDUZLIMNWCMSDO-UHFFFAOYSA-N 2-[3-[1-(3-methylphenyl)-5-propoxypyrrol-2-yl]propylideneamino]guanidine Chemical compound CCCOC1=CC=C(CCC=NNC(N)=N)N1C1=CC=CC(C)=C1 DDUZLIMNWCMSDO-UHFFFAOYSA-N 0.000 claims 1
- SKVSXQOINGZNIB-UHFFFAOYSA-N 2-[3-[1-(3-tert-butylphenyl)-5-(2-methylpropanoyl)pyrrol-2-yl]propylideneamino]guanidine Chemical compound CC(C)C(=O)C1=CC=C(CCC=NNC(N)=N)N1C1=CC=CC(C(C)(C)C)=C1 SKVSXQOINGZNIB-UHFFFAOYSA-N 0.000 claims 1
- RPMJBFFBFZYOLJ-UHFFFAOYSA-N 2-[3-[1-(4-bromophenyl)-4-tert-butylpyrrol-3-yl]propylideneamino]guanidine Chemical compound C1=C(CCC=NNC(N)=N)C(C(C)(C)C)=CN1C1=CC=C(Br)C=C1 RPMJBFFBFZYOLJ-UHFFFAOYSA-N 0.000 claims 1
- XKEKCURPQOKKLI-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(2-phenylethyl)pyrrol-3-yl]propylideneamino]guanidine Chemical compound C=1C=C(Cl)C=CC=1N1C=C(CCC=NNC(=N)N)C=C1CCC1=CC=CC=C1 XKEKCURPQOKKLI-UHFFFAOYSA-N 0.000 claims 1
- QZNMIMTUJKJWFT-UHFFFAOYSA-N 2-[3-[1-[2-(2-methylpropanoyl)phenyl]-5-nitropyrrol-2-yl]propylideneamino]guanidine Chemical compound CC(C)C(=O)C1=CC=CC=C1N1C([N+]([O-])=O)=CC=C1CCC=NNC(N)=N QZNMIMTUJKJWFT-UHFFFAOYSA-N 0.000 claims 1
- RIGFKRQEUSRNCB-UHFFFAOYSA-N 2-[3-[1-[4-(propylamino)phenyl]-5-(trichloromethyl)pyrrol-3-yl]propylideneamino]guanidine Chemical compound C1=CC(NCCC)=CC=C1N1C(C(Cl)(Cl)Cl)=CC(CCC=NNC(N)=N)=C1 RIGFKRQEUSRNCB-UHFFFAOYSA-N 0.000 claims 1
- WSOPGEABKBOEBI-UHFFFAOYSA-N 2-[3-[1-[4-(trifluoromethyl)phenyl]pyrrol-2-yl]propylideneamino]guanidine Chemical compound NC(=N)NN=CCCC1=CC=CN1C1=CC=C(C(F)(F)F)C=C1 WSOPGEABKBOEBI-UHFFFAOYSA-N 0.000 claims 1
- FTFNFTFOQNOQKR-UHFFFAOYSA-N 2-[3-[4-hydroxy-1-[3-(trichloromethyl)phenyl]pyrrol-2-yl]propylideneamino]guanidine Chemical compound NC(=N)NN=CCCC1=CC(O)=CN1C1=CC=CC(C(Cl)(Cl)Cl)=C1 FTFNFTFOQNOQKR-UHFFFAOYSA-N 0.000 claims 1
- OJZDXDOJCOVPSX-UHFFFAOYSA-N 2-[3-[5-bromo-1-(4-bromophenyl)pyrrol-3-yl]propylideneamino]guanidine Chemical compound C1=C(CCC=NNC(=N)N)C=C(Br)N1C1=CC=C(Br)C=C1 OJZDXDOJCOVPSX-UHFFFAOYSA-N 0.000 claims 1
- BVMLYGPSBCWQEY-UHFFFAOYSA-N 2-[3-[5-tert-butyl-1-[2-tert-butyl-3,4-bis(trichloromethyl)phenyl]-4-(trichloromethyl)pyrrol-2-yl]propylideneamino]guanidine Chemical compound CC(C)(C)C1=C(C(Cl)(Cl)Cl)C=C(CCC=NNC(N)=N)N1C1=CC=C(C(Cl)(Cl)Cl)C(C(Cl)(Cl)Cl)=C1C(C)(C)C BVMLYGPSBCWQEY-UHFFFAOYSA-N 0.000 claims 1
- OGVIEMFMGREMAK-UHFFFAOYSA-N 2-[[1-(3,5-dichlorophenyl)pyrrol-2-yl]methylideneamino]guanidine Chemical compound NC(=N)NN=CC1=CC=CN1C1=CC(Cl)=CC(Cl)=C1 OGVIEMFMGREMAK-UHFFFAOYSA-N 0.000 claims 1
- GIJOIJFUUPGMHS-UHFFFAOYSA-N 2-[[1-(3-cyanophenyl)-5-(trifluoromethyl)pyrrol-2-yl]methylideneamino]guanidine Chemical compound NC(=N)NN=CC1=CC=C(C(F)(F)F)N1C1=CC=CC(C#N)=C1 GIJOIJFUUPGMHS-UHFFFAOYSA-N 0.000 claims 1
- NDXXQYJMEOTRML-UHFFFAOYSA-N 2-[[1-(3-cyanophenyl)pyrrol-2-yl]methylideneamino]guanidine Chemical compound NC(=N)NN=CC1=CC=CN1C1=CC=CC(C#N)=C1 NDXXQYJMEOTRML-UHFFFAOYSA-N 0.000 claims 1
- UOFHTGRABVMRGU-UHFFFAOYSA-N 2-[[1-(3-methoxyphenyl)pyrrol-2-yl]methylideneamino]guanidine Chemical compound COC1=CC=CC(N2C(=CC=C2)C=NNC(N)=N)=C1 UOFHTGRABVMRGU-UHFFFAOYSA-N 0.000 claims 1
- RYUKQNHMWPLSIM-UHFFFAOYSA-N 2-[[1-(4-chlorophenyl)pyrrol-2-yl]methylideneamino]guanidine Chemical compound NC(=N)NN=CC1=CC=CN1C1=CC=C(Cl)C=C1 RYUKQNHMWPLSIM-UHFFFAOYSA-N 0.000 claims 1
- FZOMZPQZBLDAPV-UHFFFAOYSA-N 2-[[1-(4-morpholin-4-ylphenyl)pyrrol-2-yl]methylideneamino]guanidine Chemical compound NC(=N)NN=CC1=CC=CN1C1=CC=C(N2CCOCC2)C=C1 FZOMZPQZBLDAPV-UHFFFAOYSA-N 0.000 claims 1
- NQBNBXXUCXBDST-UHFFFAOYSA-N 2-[[1-(4-pyrrolidin-1-ylphenyl)pyrrol-3-yl]methylideneamino]guanidine Chemical compound C1=C(C=NNC(=N)N)C=CN1C1=CC=C(N2CCCC2)C=C1 NQBNBXXUCXBDST-UHFFFAOYSA-N 0.000 claims 1
- LBKDGJAQSTYJRB-UHFFFAOYSA-N 2-[[1-(4-tert-butylphenyl)pyrrol-3-yl]methylideneamino]guanidine Chemical compound C1=CC(C(C)(C)C)=CC=C1N1C=C(C=NNC(N)=N)C=C1 LBKDGJAQSTYJRB-UHFFFAOYSA-N 0.000 claims 1
- UUNCOFPVAGMZTB-UHFFFAOYSA-N 2-[[1-[3-(butylamino)phenyl]pyrrol-3-yl]methylideneamino]guanidine Chemical compound CCCCNC1=CC=CC(N2C=C(C=NNC(N)=N)C=C2)=C1 UUNCOFPVAGMZTB-UHFFFAOYSA-N 0.000 claims 1
- RIJVPRBEHOHFAZ-UHFFFAOYSA-N 2-[[1-[3-nitro-4-(propylamino)phenyl]pyrrol-3-yl]methylideneamino]guanidine Chemical compound C1=C([N+]([O-])=O)C(NCCC)=CC=C1N1C=C(C=NNC(N)=N)C=C1 RIJVPRBEHOHFAZ-UHFFFAOYSA-N 0.000 claims 1
- PPWVNMANELAPNI-UHFFFAOYSA-N 2-[[1-[4-(trifluoromethyl)phenyl]pyrrol-2-yl]methylideneamino]guanidine Chemical compound NC(=N)NN=CC1=CC=CN1C1=CC=C(C(F)(F)F)C=C1 PPWVNMANELAPNI-UHFFFAOYSA-N 0.000 claims 1
- MZTZASGDJFVFDC-UHFFFAOYSA-N 2-[[4-bromo-1-(2-butoxy-3-propoxyphenyl)pyrrol-2-yl]methylideneamino]guanidine Chemical compound CCCCOC1=C(OCCC)C=CC=C1N1C(C=NNC(N)=N)=CC(Br)=C1 MZTZASGDJFVFDC-UHFFFAOYSA-N 0.000 claims 1
- QZMGNACMDLSVQT-UHFFFAOYSA-N 2-[[4-chloro-1-(4-phenylphenyl)pyrrol-2-yl]methylideneamino]guanidine Chemical compound NC(=N)NN=CC1=CC(Cl)=CN1C1=CC=C(C=2C=CC=CC=2)C=C1 QZMGNACMDLSVQT-UHFFFAOYSA-N 0.000 claims 1
- VRLSMXYJKOFIQU-UHFFFAOYSA-N 2-[[4-cyano-1-(2-methylphenyl)pyrrol-3-yl]methylideneamino]guanidine Chemical compound CC1=CC=CC=C1N1C=C(C#N)C(C=NNC(N)=N)=C1 VRLSMXYJKOFIQU-UHFFFAOYSA-N 0.000 claims 1
- KPVUGXNNMRLPMI-UHFFFAOYSA-N 2-[[4-methyl-5-(propylamino)-1-[3-(trichloromethyl)phenyl]pyrrol-3-yl]methylideneamino]guanidine Chemical compound CCCNC1=C(C)C(C=NNC(N)=N)=CN1C1=CC=CC(C(Cl)(Cl)Cl)=C1 KPVUGXNNMRLPMI-UHFFFAOYSA-N 0.000 claims 1
- VSQMMKCSRIPRFT-UHFFFAOYSA-N 2-[[4-pentyl-1-[2-(trichloromethyl)phenyl]pyrrol-3-yl]methylideneamino]guanidine Chemical compound C1=C(C=NNC(N)=N)C(CCCCC)=CN1C1=CC=CC=C1C(Cl)(Cl)Cl VSQMMKCSRIPRFT-UHFFFAOYSA-N 0.000 claims 1
- WXJZHIAYBSYOPB-UHFFFAOYSA-N 2-[[5-(2-methylpropanoyl)-1-(2,3,4-trimethoxyphenyl)pyrrol-2-yl]methylideneamino]guanidine Chemical compound COC1=C(OC)C(OC)=CC=C1N1C(C(=O)C(C)C)=CC=C1C=NNC(N)=N WXJZHIAYBSYOPB-UHFFFAOYSA-N 0.000 claims 1
- QCAMYVMCLAUCEN-UHFFFAOYSA-N 2-[[5-chloro-1-[4-(2-methylpropanoyl)phenyl]-4-pentylpyrrol-2-yl]methylideneamino]guanidine Chemical compound ClC1=C(CCCCC)C=C(C=NNC(N)=N)N1C1=CC=C(C(=O)C(C)C)C=C1 QCAMYVMCLAUCEN-UHFFFAOYSA-N 0.000 claims 1
- KOSPSPGTPGQSLG-UHFFFAOYSA-N 2-[[5-hydroxy-1-(2-hydroxyphenyl)pyrrol-3-yl]methylideneamino]guanidine Chemical compound C1=C(C=NNC(=N)N)C=C(O)N1C1=CC=CC=C1O KOSPSPGTPGQSLG-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- PTNJNTACFJEMIC-UHFFFAOYSA-N CCCCOC1=CC=CC=C1N1C(C=NNC(N)=N)=CC=C1NCCC Chemical compound CCCCOC1=CC=CC=C1N1C(C=NNC(N)=N)=CC=C1NCCC PTNJNTACFJEMIC-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 210000004324 Lymphatic System Anatomy 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- GCYSAAKDBFDTPO-UHFFFAOYSA-N NC(=N)NN=CC1=CC=C(O)N1C1=CC=C(N)C=C1 Chemical compound NC(=N)NN=CC1=CC=C(O)N1C1=CC=C(N)C=C1 GCYSAAKDBFDTPO-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 210000000578 Peripheral Nerves Anatomy 0.000 claims 1
- 206010037175 Psychiatric disease Diseases 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 1
- 230000000172 allergic Effects 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
- 230000003054 hormonal Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 229940113083 morpholine Drugs 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002285 radioactive Effects 0.000 claims 1
- 201000001880 sexual dysfunction Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims 1
Claims (46)
- 一般式(I)で表される化合物とその互変異性体、または薬理学的に活性なその塩。
R1、R2、R3、R4およびR5は、同じであっても異なっていてもよく、水素、ハロゲン、炭素原子を1〜5個有するアルキル、炭素原子を1〜5個有するアルコキシ、ヒドロキシ、アルキルスルホニルオキシ、シアノ、ニトロ、トリハロアルキル、スルホ、および以下に示す構造のいずれかから選択され、
R6、R7、R8およびR9は、同じであっても異なっていてもよく、水素、ハロゲン、炭素原子を1〜5個有するアルキル、炭素原子を1〜5個有するアルコキシ、ヒドロキシ、炭素原子を0、1または2個有するアミン(第1級、第2級または第3級)、シアノ、ニトロ、トリハロアルキル、アミド、またはスルホから選択され、ここで示すzは、フェニルまたはピロール環に対する残基の結合箇所を表す。 - 置換基R1、R2、R3、R4およびR5のうち少なくとも2つが水素である請求項1に記載の化合物。
- アルキルがメチル、エチル、n-ブチル、n-ペンチルまたはt-ブチルから選択される請求項1または2に記載の化合物。
- アルコキシがメトキシ、エトキシ、プロピルオキシ、ブトキシまたはt-ブトキシから選択される請求項1〜3のいずれかに記載の化合物。
- R6、R7およびR8が水素である請求項1〜4のいずれかに記載の化合物。
- ハロゲンがフルオロ、クロロまたはブロモから選択される請求項1〜5のいずれかに記載の化合物。
- n=0である請求項1〜6のいずれかに記載の化合物。
- R5が水素である請求項1〜7のいずれかに記載の化合物。
- R3が水素である請求項1〜8のいずれかに記載の化合物。
- R4が水素である請求項1〜9のいずれかに記載の化合物。
- -X-CH=N-NH-C(=NH)-NH2部分がピロール環の2位にある請求項1〜10のいずれかに記載の化合物。
- R1およびR2がフェニル環の3位、4位または5位に位置する請求項1〜11のいずれかに記載の化合物。
- R2が水素である請求項1〜12のいずれかに記載の化合物。
- R1がフェニル環の4位にある請求項1〜13のいずれかに記載の化合物。
- R1がアルキル、アルコキシ、ハロゲン、水素、アミノまたはトリハロアルキルから選択される請求項1〜14のいずれかに記載の化合物。
- R1がハロゲン、水素、トリハロアルキルまたはモルホリンから選択される請求項15に記載の化合物。
- ハロゲンが、クロロまたはブロモから選択される請求項16に記載の化合物。
- ハロゲンが、クロロである請求項16に記載の化合物。
- トリハロアルキルがトリフルオロメチルまたはトリクロロメチルから選択される請求項16に記載の化合物。
- トリハロアルキルが、トリフルオロメチルである請求項16に記載の化合物。
- 下記式のうちいずれか一つを有する請求項1に記載の化合物または薬理学的に許容可能なその塩。
番号 化合物名
1 N-[1-[(4-Chlorophenyl)-1H-Pyrrol-2-yl]methyleneamino]guanidine
2 N-[1-(5-propylamino-1-(2-butoxyphenyl)-1H-pyrrol-2-yl)-methyleneamino]-guanidine
3 N-[3-[1-(2-Isobutyrylphenyl)-5-nitro-1H-pyrrol-2-yl]-propylideneamino]-guanidine
4 N-[1-[1-(3-Cyanophenyl)-5-trifluoromethyl-1H-pyrrol-2-yl]-methyleneamino]-guanidine
5 N-[3-[1-(3-Fluorophenyl)-5-methyl-1H-pyrrol-3-yl]-propylideneamino]-guanidine
6 N-[1-(4-Aminophenyl)-5-hydroxy-1H-pyrrol-2-ylmethylideneamino]-guanidine
7 N-[3-[1-(4-Chlorophenyl)-5-phenethyl-1H-pyrrol-3-yl]-propylideneamino]-guanidine
8 N-[3-[1-(4-Propylaminophenyl)-5-trichloromethyl-1H-pyrrol-3-yl]-propylideneamino]-guanidine
9 N-(5-tert-Butyl-1-phenyl-1H-pyrrol-2-ylmethylideneamino)-guanidine
10 N-[3-(5-Methoxy-1-phenyl-1H-pyrrol-3-yl)-propylideneamino]-guanidine
11 N-[4-Pentyl-1-(2-trichloromethylphenyl)-1H-pyrrol-3-ylmethylideneamino]-guanidine
12 N-(4-Cyano-1-o-tolyl-1H-pyrrol-3-ylmethylideneamino)-guanidine
13 N-[3-[4-Hydroxy-1-(3-trichloromethylphenyl)-1H-pyrrol-2-yl]-propylideneamino]-guanidine
14 N-[3-[1-(3-tert-Butylphenyl)-5-isobutyryl-1H-pyrrol-2-yl]-propylideneamino]-guanidine
15 N-(1-Biphenyl-4-yl-4-chloro-1H-pyrrol-2-ylmethylideneamino)-guanidine
16 N-[3-[1-(4-Bromophenyl)-4-tert-butyl-1H-pyrrol-3-yl]-propylideneamino]-guanidine
17 N-(4-Butoxy-1-phenyl-1H-pyrrol-3-ylmethylideneamino)-guanidine
18 N-[3-(4-Methoxy-1-phenyl-1H-pyrrol-2-yl)-propylideneamino]-guanidine
19 N-[3-[1-(2-Nitrophenyl)-1H-pyrrol-2-yl]-propylideneamino]-guanidine
20 N-[3-[1-(2-Hydroxyphenyl)-1H-pyrrol-2-yl]-propylideneamino]-guanidine
21 N-[1-(3-Methoxyphenyl)-1H-pyrrol-2-ylmethylideneamino]-guanidine
22 N-[1-(3-Butylaminophenyl)-1H-pyrrol-3-ylmethylideneamino]-guanidine
23 N-[1-(4-tert-Butylphenyl)-1H-pyrrol-3-ylmethylideneamino]-guanidine
24 N-[3-[1-(4-Trifluoromethylphenyl)-1H-pyrrol-2-yl]-propylideneamino]-guanidine
25 N-(1-Phenyl-1H-pyrrol-3-ylmethylideneamino)-guanidine
26 N-[3-(1-Phenyl-1H-pyrrol-2-yl)-propylideneamino]-guanidine
29 N-[3-(4-Methyl-1-phenyl-1H-pyrrol-3-yl)-propylideneamino]-guanidine
30 N-[1-(3-Nitro-4-propylaminophenyl)-1H-pyrrol-3-ylmethylideneamino]-guanidine
31 N-[3-[1-(3-Butylamino-4-methylphenyl)-4-methyl-1H-pyrrol-2-yl]-propylidene]-guanidine
32 N-[3-[5-Bromo-1-(4-bromophenyl)-1H-pyrrol-3-yl]-propylideneamino]-guanidine
33 N-[(5-Chloro-1-(4-isobutyrylphenyl)-4-pentyl-1H-pyrrol-2-yl)methyleneamino]-guanidine
34 N-[3-(5-Propoxy-1-m-tolyl-1H-pyrrol-2-yl)-propylideneamino]-guanidine
35 N-[4-Methyl-5-propylamino-1-(3-trichloromethyl-phenyl)-1H-pyrrol-3-ylmethylideneamino]-guanidine
36 N-[3-[1-(3-Nitro-biphenyl-4-yl)-1H-pyrrol-2-yl]-propylideneamino]-guanidine
37 N-[2-[4-tert-Butyl-1-(4-methoxy-2-propylaminophenyl)-1H-pyrrol-3-yl]-ethylideneamino]-guanidine
38 N-[3-[1-(2-Bromo-3-chlorophenyl)-1H-pyrrol-3-yl]-propylideneamino]-guanidine
39 N-[4-Bromo-1-(2-butoxy-3-propoxyphenyl)-1H-pyrrol-2-ylmethylideneamino]-guanidine
40 N-[5-Hydroxy-1-(2-hydroxyphenyl)-1H-pyrrol-3-ylmethylideneamino]-guanidine
41 N-[3-[1-(2-tert-Butylphenyl)-4-chloro-5-methyl-1H-pyrrol-2-yl]-propylideneamino]-guanidine
42 N-[5-Isobutyryl-1-(2,3,4-trimethoxyphenyl)-1H-pyrrol-2-ylmethylideneamino]-guanidine
43 N-[3-[5-tert-Butyl-1-(2-tert-butyl-3,4-bis-trichloromethylphenyl)-4-trichloromethyl-1H-pyrrol-2-yl]-propylideneamino]-guanidine
44 N-[2-[1-(4-Pyrrol-1-ylphenyl)-1H-pyrrol-2-yl]-ethylideneamino]-guanidine
45 N-[1-(4-Morpholin-4-ylphenyl)-1H-pyrrol-2-ylmethylideneamino]-guanidine
46 N-[1-(4-Pyrrolidin-1-ylphenyl)-1H-pyrrol-3-ylmethylidenamino]-guanidine
47 N-((1-Phenyl-1H-pyrrol-2-yl)methyleneamino)guanidine
48 N-[(1-(4-Trifluoromethylphenyl)-1H-pyrrol-2-yl)methyleneamino]guanidine
49 N-[(1-(3-cyanophenyl)-1H-pyrrol-2-yl)methyleneamino]guanidine
50 N-[(1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl)methyleneamino]guanidine - 標識、放射性標識、または毒物(toxic agent)をさらに含む請求項1〜21のいずれか1項に記載の化合物。
- 請求項1〜22のいずれか1項に記載の化合物と、1以上の佐剤(adjuvants)、担体または賦形剤とを含む医薬品組成物。
- 治療に用いる請求項1〜22のいずれか1項に記載の化合物。
- 請求項1〜22のいずれか1項に記載の化合物を含む、炎症の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、精神障害(disorders)の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、内分泌系またはホルモン系における機能不全の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、性機能および/または性機能不全の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、血液および/またはリンパ系における薬物性またはそれ以外の障害の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、アレルギー性疾患(disorders)の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、心血管系における障害の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、痛みの治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、皮膚の日焼けまたは皮膚の淡色化を誘発する薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、II型糖尿病の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、肥満の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、食欲不振の治療薬。
- 前記食欲不振が、癌、カヘキシー、高齢(geriatric conditions)、HIV、外傷、または心理状態に起因する食欲不振である、請求項37に記載の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、末梢神経の再生を誘発する薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、中枢神経の再生を誘発する薬。
- 請求項1〜22のいずれか1項に記載の化合物の使用または投与を含む、皮膚の日焼けまたは皮膚の淡色化を誘発する方法。
- 請求項1〜22のいずれか1項に記載の化合物を含む、皮膚障害の治療薬。
- 前記皮膚障害が黒色腫である、請求項42に記載の治療薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、悪性腫瘍の治療および/または診断のための薬。
- 前記悪性腫瘍が黒色腫および/または転移である、請求項44に記載の薬。
- 請求項1〜22のいずれか1項に記載の化合物を含む、虚血および/または虚血/再灌流の治療薬。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0119172.5A GB0119172D0 (en) | 2001-08-06 | 2001-08-06 | Phenyl pyrrole derivatives |
PCT/GB2002/003620 WO2003013509A1 (en) | 2001-08-06 | 2002-08-06 | N-phenylpyrrole guanidine derivatives as melanocortin reception ligands |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009143997A Division JP2009242414A (ja) | 2001-08-06 | 2009-06-17 | メラノコルチンレセプターリガンドとしてのn−フェニルピロールグアニジン誘導体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005504039A JP2005504039A (ja) | 2005-02-10 |
JP2005504039A5 true JP2005504039A5 (ja) | 2006-01-12 |
JP4450620B2 JP4450620B2 (ja) | 2010-04-14 |
Family
ID=9919909
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003518518A Expired - Fee Related JP4450620B2 (ja) | 2001-08-06 | 2002-08-06 | メラノコルチンレセプターリガンドとしてのn−フェニルピロールグアニジン誘導体 |
JP2009143997A Withdrawn JP2009242414A (ja) | 2001-08-06 | 2009-06-17 | メラノコルチンレセプターリガンドとしてのn−フェニルピロールグアニジン誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009143997A Withdrawn JP2009242414A (ja) | 2001-08-06 | 2009-06-17 | メラノコルチンレセプターリガンドとしてのn−フェニルピロールグアニジン誘導体 |
Country Status (19)
Country | Link |
---|---|
US (3) | US7186748B2 (ja) |
EP (1) | EP1414440B1 (ja) |
JP (2) | JP4450620B2 (ja) |
KR (1) | KR20040019302A (ja) |
AU (1) | AU2002313542B2 (ja) |
BR (1) | BR0210445A (ja) |
CA (1) | CA2448356C (ja) |
CY (1) | CY1106424T1 (ja) |
DE (1) | DE60217503T2 (ja) |
DK (1) | DK1414440T3 (ja) |
ES (1) | ES2280555T3 (ja) |
GB (1) | GB0119172D0 (ja) |
IL (1) | IL160181A0 (ja) |
MX (1) | MXPA04001037A (ja) |
NO (1) | NO20040465L (ja) |
NZ (1) | NZ529666A (ja) |
PT (1) | PT1414440E (ja) |
SI (1) | SI1414440T1 (ja) |
WO (1) | WO2003013509A1 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
EP1425029A4 (en) | 2001-08-10 | 2006-06-07 | Palatin Technologies Inc | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES |
BR0306811A (pt) | 2002-01-11 | 2004-10-26 | Sankyo Co | Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
GB2398299A (en) * | 2003-02-13 | 2004-08-18 | Melacure Therapeutics Ab | Pharmaceutically active phenyl-pyrrole derivatives |
WO2005079788A1 (ja) | 2004-02-24 | 2005-09-01 | Sankyo Company, Limited | アミノアルコール化合物 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
MX2008015454A (es) | 2006-06-09 | 2009-01-30 | Action Pharma As | Derivados de fenil-pirrol-aminoguanidina. |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2170930B3 (en) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2155643B1 (en) | 2007-06-08 | 2016-08-10 | MannKind Corporation | Ire-1a inhibitors |
EP2045250A1 (en) * | 2007-09-26 | 2009-04-08 | Action Pharma A/S | Ring-substituted phenyl pyrrole aminoguanidine derivatives |
WO2009071101A1 (en) * | 2007-12-07 | 2009-06-11 | Action Pharma A/S | N-modified aminoguanidine derivatives |
WO2009074157A1 (en) * | 2007-12-13 | 2009-06-18 | Action Pharma A/S | Fully-modified phenyl pyrrole aminoguanidines |
EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
JP5688366B2 (ja) | 2008-08-15 | 2015-03-25 | エヌサーティー・ファーマシューティカルズ・インコーポレーテッド | 治療薬剤としての、s−ニトロソグルタチオンレダクターゼの新規ピロール阻害剤 |
DK2315590T3 (da) | 2008-08-15 | 2012-11-19 | N30 Pharmaceuticals Inc | Pyrrolinhibitorer af S-nitrosoglutathionreduktase |
CA2734154C (en) | 2008-08-15 | 2017-07-11 | N30 Pharmaceuticals, Llc | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
CA2743489A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
EP2298541A1 (en) | 2009-09-17 | 2011-03-23 | Rieter Technologies AG | Moulded automotive part |
TR201802311T4 (tr) | 2009-09-16 | 2018-03-21 | Autoneum Man Ag | Otomotiv panelleri için kalıplanmış ürün. |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
PL2502788T3 (pl) | 2011-03-23 | 2014-08-29 | Autoneum Man Ag | Sposób wytwarzania formowanej wielowarstwowej wykładziny |
EP2503040A1 (en) | 2011-03-23 | 2012-09-26 | Autoneum Management AG | Moulded multilayer lining |
EP2602248A1 (en) | 2011-12-05 | 2013-06-12 | University Of Leicester | Novel pyrrole compounds |
RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
US9319414B2 (en) | 2012-11-29 | 2016-04-19 | Jeffry David Aronson | Scalable full spectrum cyber determination process |
US8434136B1 (en) | 2012-11-29 | 2013-04-30 | Jeffry David Aronson | Full spectrum cyber identification determination process |
CA2898482A1 (en) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Antidiabetic bicyclic compounds |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
US10233179B2 (en) | 2013-04-22 | 2019-03-19 | Abbvie Inc. | Thiazoles and uses thereof |
BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
KR20220004996A (ko) | 2019-04-03 | 2022-01-12 | 알리고스 테라퓨틱스 인코포레이티드 | 피롤 화합물 |
CN113651673A (zh) * | 2021-07-01 | 2021-11-16 | 烟台泰和新材料股份有限公司 | 一种芳烃侧链甲基氯代物的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9604348D0 (sv) * | 1996-11-26 | 1996-11-26 | Wapharm Ab | Användning av hydroxyguanidiner |
WO1999055679A1 (en) * | 1998-04-28 | 1999-11-04 | Trega Biosciences, Inc. | Isoquinoline compound melanocortin receptor ligands and methods of using same |
WO2001025192A1 (en) * | 1999-10-06 | 2001-04-12 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
GB0019359D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
GB0108631D0 (en) * | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
US6951881B2 (en) * | 2002-05-10 | 2005-10-04 | Wyeth | (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands |
-
2001
- 2001-08-06 GB GBGB0119172.5A patent/GB0119172D0/en not_active Ceased
-
2002
- 2002-08-06 PT PT02753136T patent/PT1414440E/pt unknown
- 2002-08-06 AU AU2002313542A patent/AU2002313542B2/en not_active Ceased
- 2002-08-06 DE DE60217503T patent/DE60217503T2/de not_active Expired - Lifetime
- 2002-08-06 EP EP02753136A patent/EP1414440B1/en not_active Expired - Lifetime
- 2002-08-06 DK DK02753136T patent/DK1414440T3/da active
- 2002-08-06 IL IL16018102A patent/IL160181A0/xx unknown
- 2002-08-06 NZ NZ529666A patent/NZ529666A/en not_active IP Right Cessation
- 2002-08-06 BR BR0210445-8A patent/BR0210445A/pt not_active IP Right Cessation
- 2002-08-06 KR KR10-2003-7016099A patent/KR20040019302A/ko not_active Application Discontinuation
- 2002-08-06 WO PCT/GB2002/003620 patent/WO2003013509A1/en active IP Right Grant
- 2002-08-06 CA CA2448356A patent/CA2448356C/en not_active Expired - Fee Related
- 2002-08-06 ES ES02753136T patent/ES2280555T3/es not_active Expired - Lifetime
- 2002-08-06 US US10/484,444 patent/US7186748B2/en not_active Expired - Fee Related
- 2002-08-06 MX MXPA04001037A patent/MXPA04001037A/es unknown
- 2002-08-06 JP JP2003518518A patent/JP4450620B2/ja not_active Expired - Fee Related
- 2002-08-06 SI SI200230506T patent/SI1414440T1/sl unknown
-
2004
- 2004-02-02 NO NO20040465A patent/NO20040465L/no not_active Application Discontinuation
-
2006
- 2006-03-15 US US11/374,956 patent/US7442807B2/en not_active Expired - Fee Related
-
2007
- 2007-03-30 CY CY20071100446T patent/CY1106424T1/el unknown
-
2008
- 2008-09-17 US US12/232,399 patent/US20090018183A1/en not_active Abandoned
-
2009
- 2009-06-17 JP JP2009143997A patent/JP2009242414A/ja not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005504039A5 (ja) | ||
CA2448356A1 (en) | N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands | |
Surry et al. | Diamine ligands in copper-catalyzed reactions | |
AU2004213616B2 (en) | A process of preparing imatinib | |
US4916129A (en) | Combination β-blocking/angiotensin II blocking antihypertensives | |
JP2004517840A (ja) | フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用 | |
JP2005535586A5 (ja) | ||
US11535598B2 (en) | Histone deacetylases (HDACs) inhibitors | |
RU2264389C3 (ru) | Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения | |
DE60235500D1 (de) | Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung | |
JP2007505922A5 (ja) | ||
CA2037630A1 (en) | Nitrogen-containing heterocylic compounds, their production and use | |
JP2004528334A5 (ja) | ||
CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
JP2011524422A5 (ja) | ||
RU2007116987A (ru) | Новые соединения | |
RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
RU2005124360A (ru) | Новые обратные агонисты рецептора св 1 | |
JP2005518414A5 (ja) | ||
JP2007520440A5 (ja) | ||
JP2008508217A (ja) | Hsp90の阻害剤 | |
JP2008510719A5 (ja) | ||
Nenajdenko et al. | Convenient synthesis of melatonin analogues: 2-and 3-substituted-N-acetylindolylalkylamines | |
JP5087171B2 (ja) | 5−ヒドロキシトリプタミン−6リガンドとしての1−(アリールスルホニル)−4−(ピペラジン−1−イル)−1h−ベンズイミダゾール類 | |
WO2021175079A1 (zh) | 对苯二胺类lsd1抑制剂及其制备方法 |